Sagimet Biosciences (SGMT)

The company’s lead candidate is denifanstat, an oral, once-daily and selective FASN inhibitor. Sagimet is developing denifanstat primarily for metabolic dysfunction-associated steatohepatitis, or MASH, a serious liver disease associated with fat accumulation, inflammation, and progressive scarring of liver tissue. MASH has become a major area of drug development because it is linked to obesity, diabetes, and metabolic syndrome, and because advanced cases can lead to cirrhosis, liver failure, or the need for transplant.

Denifanstat is also being evaluated for other conditions where FASN biology may be relevant, including acne and selected cancers. Sagimet’s second FASN inhibitor, TVB-3567, is a small-molecule candidate being developed for acne. By targeting palmitate overproduction and related metabolic pathways, the company aims to address disease mechanisms rather than only treating symptoms.

Sagimet operates as a single business segment centered on the discovery, development, and potential commercialization of FASN inhibitors. Like other clinical-stage biopharmaceutical companies, it does not have the same operating profile as a commercial drugmaker; its value depends heavily on clinical trial results, regulatory progress, financing capacity, intellectual property, and the competitive landscape in liver disease, dermatology, and oncology.